Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
14.74
+0.55 (3.88%)
At close: Aug 12, 2025, 4:00 PM
14.72
-0.02 (-0.14%)
After-hours: Aug 12, 2025, 7:56 PM EDT
Lumos Pharma Employees
Arcutis Biotherapeutics had 342 employees as of December 31, 2024. The number of employees increased by 46 or 15.54% compared to the previous year.
Employees
342
Change (1Y)
46
Growth (1Y)
15.54%
Revenue / Employee
$770,365
Profits / Employee
-$272,722
Market Cap
1.77B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 342 | 46 | 15.54% |
Dec 31, 2023 | 296 | 28 | 10.45% |
Dec 31, 2022 | 268 | 121 | 82.31% |
Dec 31, 2021 | 147 | 93 | 172.22% |
Dec 31, 2020 | 54 | 25 | 86.21% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ARQT News
- 4 days ago - Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 days ago - Arcutis Biotherapeutics, Inc. (ARQT) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 11 days ago - Arcutis: Leveraging Zoryve's Success While Positioning For Pipeline Expansion - Seeking Alpha
- 20 days ago - Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025 - GlobeNewsWire
- 6 weeks ago - Arcutis Biotherapeutics: A Closer Look At The Atopic Dermatitis Direction - Seeking Alpha
- 6 weeks ago - Arcutis' ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis - GlobeNewsWire
- 6 weeks ago - Arcutis Biotherapeutics: Another Approval Under Their Belt - Seeking Alpha